Line design
Hetlioz® (tasimelteon)

Case Name: Vanda Pharms. Inc. v. Teva Pharms. USA, Inc., C.A. Nos. 23-152-JLH, 23-153-JLH, 2026 WL 2875089 (D. Del. Sept. 24, 2026) (Hall, J.)

Drug Product and Patent(s)-in-Suit: Hetlioz® (tasimelteon); U.S. Patent Nos. 11,285,129 (“the ’129 patent”) and 11,918,556 (“the ’556 patent”)

Nature of the Case and Issue(s) Presented: Hetlioz is Vanda’s 20 mg tasimelteon drug approved to treat Non-24-Hour Sleep-Wake Disorder (“Non-24”). Teva and Apotex filed ANDAs seeking approval to market generic 20 mg tasimelteon capsules. In earlier litigation, Chief Judge Connolly found Vanda’s then-asserted method-of-treatment claims invalid as obvious, and the Federal Circuit affirmed. After the ’129 patent issued, Vanda brought new infringement actions against Teva and Apotex, which were transferred from New Jersey to Delaware. Vanda later asserted the ’556 patent after it issued in March 2024.

The ’129 and ’556 patents concern the interaction between tasimelteon and beta-adrenergic receptor antagonists (“beta blockers”). The ’129 patent claims a method requiring a determination whether the patient is taking a beta blocker. If the patient is not, the method calls for administering 20 mg tasimelteon approximately one-half hour to one-and-one-half hours before bedtime; if the patient is taking a beta blocker, the method requires instructing the patient to discontinue the beta blocker before administering tasimelteon. The ’556 patent similarly claims discontinuing beta-blocker treatment and then administering 20 mg tasimelteon, thereby avoiding decreased efficacy from co-administration.

The generic labels recommend 20 mg tasimelteon one hour before bedtime. Their drug-interactions section states that nighttime administration of beta blockers “may reduce the efficacy of tasimelteon,” but, unlike the warnings concerning certain other interacting drugs, does not instruct prescribers to avoid concomitant use of tasimelteon and beta blockers or to discontinue beta blockers. Vanda asserted direct, induced, contributory, and § 271(e)(2)(A) infringement. Following the Supreme Court’s June 2026 decision in Hikma v. Amarin, Judge Hall invited supplemental briefing concerning Hikma’s effect on Vanda’s inducement theory and ultimately granted summary judgment of noninfringement on all asserted theories.

Why Defendants Prevailed: The court held that Vanda could not establish induced infringement because, under Hikma, no reasonable jury could find that the generic labels took “active steps” to encourage infringement. Vanda acknowledged that the labels were its only evidence of inducement. Although the labels stated that nighttime administration of beta blockers may reduce tasimelteon’s efficacy, they did not instruct physicians to discontinue beta blockers. Applying Hikma, the court explained that inducing conduct need not be express, but it must constitute a clear and affirmative step that “encourage[s], recommend[s], or promote[s]” infringement. Merely providing information that could be understood as suggesting an infringing course of action was insufficient. The court also rejected Vanda’s attempt to distinguish Hikma because it involved a section viii carve-out, holding that Hikma’s reasoning was not limited to the carve-out context.

The court also granted summary judgment on contributory infringement. As to the ’129 patent, Vanda was required to show that the generic tasimelteon products had no substantial non-infringing uses. Vanda relied on the labels, FDA guidance, and expert testimony that prescribers generally determine what medications their patients are taking and that prescribers who learn a patient is taking a beta blocker should consider discontinuing it before administering tasimelteon. But Vanda had no direct evidence that any physician had actually performed all of the claimed steps, and its expert could say only that “some” or “most” prescribers would follow the claimed method. More importantly, the record contained evidence of real-world patients taking tasimelteon together with beta blockers. The court therefore concluded that no reasonable jury could find that the generic products lacked substantial non-infringing uses.

Finally, the court was skeptical that § 271(e)(2)(A) had any continuing role because the ANDAs had already been approved and the generic products had been commercially marketed for years; indeed, the ’556 patent did not issue until after both defendants had launched. Regardless, the § 271(e)(2)(A) claim failed on the merits for the same reasons as Vanda’s other infringement theories. Vanda also did not pursue direct infringement under § 271(a), acknowledging at oral argument that Teva and Apotex themselves did not practice the claimed treatment methods.

GENERICally Speaking Hatch Waxman Bulletin

Jump to Page

Robins Kaplan LLP Cookie Preference Center

Your Privacy

When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use Cookies, please see our Privacy Policy.

Strictly Necessary Cookies

Always Active

Necessary cookies enable core functionality such as security, network management, and accessibility. These cookies may only be disabled by changing your browser settings, but this may affect how the website functions.

Functional Cookies

Always Active

Some functions of the site require remembering user choices, for example your cookie preference, or keyword search highlighting. These do not store any personal information.

Form Submissions

Always Active

When submitting your data, for example on a contact form or event registration, a cookie might be used to monitor the state of your submission across pages.

Performance Cookies

Performance cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.

Powered by Firmseek